Fintel reports that on October 6, 2025, Stifel maintained coverage of Alnylam Pharmaceuticals (NasdaqGS:ALNY) with a Buy ...

Fintel reports that on October 6, 2025, Morgan Stanley maintained coverage of Alnylam Pharmaceuticals (NasdaqGS:ALNY) with a ...

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) is among the most promising biotech stocks to buy according to hedge funds.

The company was one of many to get letters last month from the US Food and Drug Administration calling out what the agency ...

The VanEck Biotech ETF (BBH) provides market-cap-weighted exposure to leading U.S.-listed biotechnology firms.

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) ranks among the best biotech stocks to buy. RBC Capital maintained its Outperform rating for Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) on September 19 and ...

Our RNAi play came from the understanding that personalization and the development of curated therapies are the future of ...

Alnylam Pharmaceuticals ( NASDAQ: ALNY) has pulled a television ad for its drug Amvuttra (vutrisiran) after the U.S. FDA determined the spot was misleading. Amvuttra is approved for two heart ...

Detailed price information for Alnylam Pharmaceuticals (ALNY-Q) from The Globe and Mail including charting and trades.

Alnylam joins Illumina and NashBio’s Alliance for Genomic Discovery to expand its 250,000 genome dataset and fuel RNAi research.

George Tidmarsh, head of the FDA’s Center for Drug Evaluation and Research, wrote that the ad incorrectly suggested patients "can be carefree" about their heart condition and "misleadingly suggests ...

Week 48 endpoint results from the SOLSTICE Phase 2 clinical study evaluating tobevibart alone or in combination with elebsiran for chronic hepatitis delta to be presented– Vir Biotechnology to ...